Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older

NCT07883928 is registered in ClinicalTrials.gov with GC Biopharma Corp as lead sponsor.

NCT NCT07883928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07883928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or Older
Lead sponsor
GC Biopharma Corp
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2028
Enrollment
1,806 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a, influenza b, influenza vaccination